Hexavest’s Regeneron Pharmaceuticals REGN Stock Holding History

Hexavest’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$11.5M	Buy	19,055 +1,466	+8%	+$910K	0.7%	43
2021 Q2	$9.82M	Sell	17,589 -810	-4%	-$410K	0.49%	68
2021 Q1	$8.71M	Sell	18,399 -3,029	-14%	-$1.47M	0.39%	91
2020 Q4	$10.4M	Sell	21,428 -10,679	-33%	-$5.76M	0.39%	82
2020 Q3	$18M	Sell	32,107 -6,147	-16%	-$3.73M	0.48%	66
2020 Q2	$23.9M	Buy	38,254 +2,259	+6%	+$1.28M	0.55%	51
2020 Q1	$17.6M	Sell	35,995 -53,043	-60%	-$21.9M	0.31%	102
2019 Q4	$33.4M	Sell	89,038 -1,268	-1%	-$427K	0.41%	97
2019 Q3	$25.1M	Buy	90,306 +1,123	+1%	+$332K	0.34%	100
2019 Q2	$27.9M	Sell	89,183 -3,250	-4%	-$1.08M	0.37%	95
2019 Q1	$38M	Buy	+92,433	New	+$38.1M	0.48%	70

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Hexavest's REGN Position: Q3 2021 in Review

Hexavest increased its Regeneron Pharmaceuticals (REGN) stake by 8.3% in Q3 2021, buying an estimated $910K and bringing the position to 19,055 shares worth $11.5M. The position accounts for 0.7% of the portfolio, ranked #43.

Hexavest first reported a position in REGN in Q1 2019 and has held it in 11 quarters since. The position peaked at $38M in Q1 2019. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Hexavest held 19,055 shares of Regeneron Pharmaceuticals worth $11.5M as of Q3 2021.
Hexavest bought 1,466 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $910K.
Regeneron Pharmaceuticals made up 0.7% of Hexavest's portfolio in Q3 2021, its #43 holding.
Hexavest first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
Hexavest's Regeneron Pharmaceuticals position peaked at $38M in Q1 2019.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Hexavest's 13F filing for Q3 2021, filed 27 Oct 2021.